Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| PHOE | Phoenix Asia | $19.13 | -$113.99 | -85.63% | 171.7K | $2.9B | $2.31$133.12 |
| AREB | American Rebel | $2.15 | -$3.40 | -61.23% | 1.6M | $44M | $2.04$13,400.00 |
| ATOS | Atossa Therapeutics | $5.95 | -$2.53 | -29.84% | 367.5K | $1.1B | $5.85$19.35 |
| LRHC | La Rosa | $2.09 | -$0.80 | -27.68% | 681.5K | $470K | $1.79$336.00 |
| IOTR | iOThree | $3.26 | -$1.15 | -26.08% | 85.3K | $11M | $2.24$59.80 |
| WHLR | Wheeler Real Estate Investment Trust | $3.52 | -$1.24 | -26.05% | 116.9K | $3.3M | $3.39$6,793.50 |
| BTOG | Bit Origin | $3.04 | -$1.01 | -24.88% | 185.8K | $9.1M | $2.58$60.60 |
| ANL | Adlai Nortye | $8.28 | -$2.35 | -22.11% | 502.5K | $332M | $0.88$11.05 |
| YEXT | Yext | $5.66 | -$1.50 | -20.95% | 63.8K | $878M | $5.51$9.20 |
| DFLI | Dragonfly Energy | $2.54 | -$0.66 | -20.66% | 998.7K | $39M | $1.50$26.10 |
| BUUU | Buuu Group | $9.12 | -$2.37 | -20.63% | 30.1K | $192M | $3.67$20.76 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $4.31 | -$1.10 | -20.33% | 9.6M | - | $4.14$35.30 |
| VIVS | VivoSim Labs | $2.38 | -$0.54 | -18.49% | 1.1M | $7.6M | $1.41$21.96 |
| TXXS | Listed Funds Trust - 21Shares 2x Long Sui ETF | $9.26 | -$2.09 | -18.40% | 29.5K | - | $9.00$30.70 |
| PHAR | Pharming Group | $16.72 | -$3.75 | -18.32% | 82.3K | $1.4B | $7.50$21.34 |
| HOOG | Themes ETF Trust - Leverage Shares 2x Long Hood Daily ETF | $33.50 | -$7.10 | -17.49% | 320.3K | - | $6.88$132.19 |
| HODU | Direxion Shares ETF Trust - Direxion Daily Hood Bull 2x ETF | $14.00 | -$2.95 | -17.40% | 42.5K | - | $13.70$35.58 |
| HOOX | Tidal Trust II - Defiance Daily Target 2x Long Hood ETF | $12.74 | -$2.67 | -17.33% | 249.1K | - | $2.26$45.53 |
| VSA | VisionSys Ai | $2.35 | -$0.49 | -17.25% | 44.7K | $2.2M | $2.18$212.04 |
| XPEG | Themes ETF Trust - Leverage Shares 2x Long Xpev Daily ETF | $9.42 | -$1.89 | -16.68% | 22.8K | - | $9.06$15.89 |
| BGM | Bgm Group | $2.96 | -$0.57 | -16.15% | 50.7K | $649M | $2.96$17.17 |
| SATL | Satellogic | $3.89 | -$0.72 | -15.54% | 9.9M | $657M | $1.26$5.93 |
| PCSA | Processa Pharmaceuticals | $2.58 | -$0.42 | -14.00% | 105.2K | $6.8M | $2.42$19.63 |
Related Articles
Featured Article
Can Atossa Therapeutics Stock Keep Climbing?
Cory Renauer|Jun 28, 2021
Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.
2 Stocks I Bought Last Week, and 1 Stock I Sold
Rick Munarriz|Nov 11, 2020
This Fool bought into a fast-growing sports-first streaming service and a disruptive mattress maker. He also sold a tech stock cashing in on the credibility gap of online search.
3 Technology Stocks I'd Buy Right Now
Jon Quast|Apr 29, 2020
Don't let current economic uncertainty keep you away from these companies with long-term potential.
My Top Growth Stock for 2020
Simon Erickson|Jan 5, 2020
After seven years of New Year's recommendations, my average pick is up 112%. See which growth-style investment I'm tapping next.
Why Zoom Video Communications, PagerDuty, and Yext Slumped Today
Dan Caplinger|Dec 6, 2019
Even on a strong day on Wall Street, poor earnings held some stocks back.
Why Carnival, Tarena International, and Genesco Slumped Today
Dan Caplinger|Jun 5, 2018
Find out which of these stocks took the biggest hit.
Where Will Organovo Holdings, Inc. Be in 5 Years?
Cory Renauer|Dec 3, 2017
Will Organovo unlock the perceived value buried deep in its organ-printing technology by 2022?
Why Tiny Organovo Is Giving Money to Huge Biotech Amgen
Keith Speights|Aug 30, 2017
Organovo is paying Amgen researchers for their ideas on studying 3D bioprinted tissues. It could be money well spent.
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
Keith Speights|Aug 10, 2017
The 3D bioprinting company beat analyst revenue estimates in its fiscal first quarter -- but its losses worsened because of higher spending.
How Risky Is Organovo Holdings, Inc.?
Keith Speights|Jul 18, 2017
Organovo might be less risky than it's been in the past, but this stock still isn't for the faint of heart.
